Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

102 results about "Sensory neuron" patented technology

Sensory neurons, also known as afferent neurons, are neurons that convert a specific type of stimulus, via their receptors, into action potentials or graded potentials. This process is called sensory transduction. The cell bodies of the sensory neurons are located in the dorsal ganglia of the spinal cord (which is part of the Central Nervous System).

Method and morphologically adaptable apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity

A method and morphologically adaptable apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity further comprising a method for using quadripolar, circular, center charged, energy balanced magnetic device in a four (4) magnet array of alternating polarity in which the magnetic poles are in multiple planes and are separated by a predetermined distance which provide an effective magnetic sphere of influence on all adjacent poles to suppress the firing of action potentials of mammalian sensory neurons. The method and apparatus further provides a static magnetic device for production of a magnetic field for treatment of various disorders that can be focused at the site of pain or edema to deliver a gradient in the magnetic field to prevent or reduce charge flow. Further there is provided a static magnetic device for production of a magnetic field for treatment of disorders wherein the device provides a static magnetic field such that the focused magnetic field gradient is oriented To be perpendicular to the neuron or membrane charge flow providing maximum deflection of the ion or charge flow.
Owner:GRADIENT TECH

Neuronal pain pathway

The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Methods of neural conversion of human embryonic stem cells

ActiveUS20120094381A1Reducing DKK- protein functionImprove featuresCulture processNervous system cellsNeural plateDirected differentiation
The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motorneurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Radioligands for the TRP-M8 receptor and methods therewith

One embodiment of the invention is a composition that comprises a radioactive [18F], [123I], [125I], or [131I]—N-radiohaloaryl-alkylcarboxamide molecule. The composition binds to the transient receptor potential-M8 (TRP-M8) receptor of cells. The TRP-M8 receptor is selectively expressed in sensory neurons and in malignant tissues such as prostate cancer cells. The [18F], [123I], [125I], or [131I]—N-radiohaloaryl-alkylcarboxamide ligand may be used for radioreceptor binding studies, for diagnostic studies, and for radiotherapy of cancerous tissues. Affinity of the [125I] or [131I]—N-radiohaloaryl-alkylcarboxamide ligand for the TRP-M8 receptor confers selectivity and specificity in delivering lethal radiation to the diseased cells.
Owner:WEI EDWARD T

Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity

A method and apparatus for altering the charge distribution upon living membranes with functional stabilizational of the membrane physical electrical integrity further comprising a method for using submicroscopic, quadripolar, circular, center charged, energy balanced magnetic device in a four (4) magnet array of alternating polarity in which the magnetic poles are separated only by a distance which will allow a magnetic sphere of influence on all adjacent poles to suppress the firing of action potentials of mammalian sensory neurons. The method and apparatus further provides a static magnetic device for production of a magnetic field for treatment of various disorders. Further there is provided a static magnetic device for production of a magnetic field for treatment of disorders wherein the device provides a static magnetic pole of like polarity on the outer surface of the flux focusing ring adjacent to each of the 4 poles of the invention (focusing magnet) such that the end r top of the focusing magnet is oriented to the geometric side of the pole such that the a six of the two magnets form a 45 to 90 degree angle.
Owner:WILSON SPENCE L

Axon regeneration from adult sensory neurons

A method for rapidly screening small molecules to identify small molecules that stimulate axon regeneration and outgrowth from adult sensory neurons. The method generally comprises preparing a purified individualized dorsal root ganglia cell suspension (DRG), coating well surfaces of a suitably prepared multi-well microplate with the DRG, then dispensing dosages of selected small molecules into selected wells. The microplates are incubated under sterile conditions at about 37° C. for at least 24 hours. The DRG suspension in each well is then morphometrically assessed to assess the extent of axon regeneration and outgrowth that occurred, and the effects of the selected small molecules are determined by comparison to control treatments. The method is suitable for screening chemically derived small molecules and biologically derived small molecules.
Owner:UNIVERSITY OF MANITOBA

Suppression of scn9a gene expression and/or function for the treatment of pain

Disclosed herein are methods, sequences and nucleic acid molecules used to treat pain. Specifically, the methods and sequences include locally administering molecules that suppress the expression of amino acid sequences that encode for Nav1.7 channels or that otherwise inhibit the function of Nav1.7 channels. Local suppression of Nav1.7 channel levels and / or function will occur in the peripheral sensory neurons of the dorsal root ganglia.
Owner:MEDTRONIC INC

Device and method responsive to influences of mind

V An anomalous effect detector (100, 130, 300, 800, 830, 840, 900, 930) responsive to an influence of mind comprises a source of non-deterministic random numbers, SNDRN, (104, 134, 310), a phase-sensitive filter (108, 140, 170, 320), and a results interface (110, 160, 340). In some embodiments, the phase-sensitive filter comprises a complex filter (170). An artificial sensory neuron (802, 810, 820, 906) comprises a SNDRN. Preferably, several artificial sensory neurons (802, 906) are grouped in a small volume. An analog artificial sensory detector (800) comprises a plurality of analog artificial sensory neurons (802), an abstracting processor (804) and a control or feedback unit (806). Some embodiments include an artificial neural network (850). An artificial consciousness network (900) contains a plurality of artificial neural networks (902, 914). One of the artificial neural networks (914) comprises an activation pattern meta-analyzer. An artificial consciousness device comprises a cluster (936) of artificial consciousness networks, a sensory input device (932) to provide sensory input signals (933) to the input of one or more ANNs in ACD (930), and an output device (938).
Owner:PSIGENICS CORP

Device and method responsive to influences of mind

V An anomalous effect detector (100, 130, 300, 800, 830, 840, 900, 930) responsive to an influence of mind comprises a source of non-deterministic random numbers, SNDRN, (104, 134, 310), a phase-sensitive filter (108, 140, 170, 320), and a results interface (110, 160, 340). In some embodiments, the phase-sensitive filter comprises a complex filter (170). An artificial sensory neuron (802, 810, 820, 906) comprises a SNDRN. Preferably, several artificial sensory neurons (802, 906) are grouped in a small volume. An analog artificial sensory detector (800) comprises a plurality of analog artificial sensory neurons (802), an abstracting processor (804) and a control or feedback unit (806). Some embodiments include an artificial neural network (850). An artificial consciousness network (900) contains a plurality of artificial neural networks (902, 914). One of the artificial neural networks (914) comprises an activation pattern meta-analyzer. An artificial consciousness device comprises a cluster (936) of artificial consciousness networks, a sensory input device (932) to provide sensory input signals (933) to the input of one or more ANNs in ACD (930), and an output device (938).
Owner:PSIGENICS CORP

Suppression of SCN9A gene expression and/or function for the treatment of pain

Disclosed herein are methods, sequences and nucleic acid molecules used to treat pain. Specifically, the methods and sequences include locally administering molecules that suppress the expression of amino acid sequences that encode for Nav1.7 channels or that otherwise inhibit the function of Nav1.7 channels. Local suppression of Nav1.7 channel levels and / or function will occur in the peripheral sensory neurons of the dorsal root ganglia.
Owner:MEDTRONIC INC

Neuromodulation of subcellular structures within the dorsal root ganglion

InactiveUS20140343624A1Suppressing action potential firingReduce conductionSpinal electrodesArtificial respirationPrimary sensory neuronSensory neuron
Devices, systems and methods are provided for the targeted treatment of abnormal sensory conditions. In such conditions, physical stimuli is transduced into neuronal impulses that are subsequently transmitted to the central nervous system for processing. Such transduction is achieved by primary sensory neurons in the dorsal root ganglions. Subcellular structures on primary sensory neurons can significantly modulate the function of these neurons, thereby affecting the transduction and reducing the abnormal sensory experiences. Thus, devices, systems and methods are provided for neuromodulating subcellular structures on primary sensory neurons of the dorsal root ganglions.
Owner:ST JUDE MEDICAL LUXEMBOURG HLDG SMI S A R L SJM LUX SMI

System and method for optogenetic therapy

One embodiment is directed to a system for controllably managing pain in the afferent nervous system of a patient having a targeted tissue structure that has been genetically modified to have light sensitive protein, comprising a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure; a light source configured to provide light to the light delivery element; and a controller operatively coupled to light source; wherein the targeted tissue structure comprises a sensory neuron of the patient; and wherein the controller is configured to be automatically operated to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.
Owner:CIRCUIT THERAPEUTICS

Detection of neureopeptides associated with pelvic pain disorders and uses thereof

Diagnostic assessment and therapeutic treatment of pelvic pain disorders, including bladder disorders, bowel disorders, and / or reproductive tissue or organ disorders that are characterized by increased expression of the neuropeptides CGRP and / or PACAP. Additionally, applicants have developed a transgenic nonhuman model for pelvic pain disorders, where the transgenic animal expresses in bladder sensory neurons a recombinant neuropeptide implicated in the pelvic pain disorder.
Owner:UNIVERSITY OF VERMONT +1

Methods and systems for automatically turning on and off DRG stimulation and adjusting DRG stimulation parameters

Methods and systems described herein can be used to automatically turn on and off stimulation of a target dorsal root ganglion (DRG) and / or adjust stimulation parameters. At least one of an input signal (indicative of an electrical field resulting from an electrical signal propagated by adjacent distal sensory nerve fibers toward the target DRG), an output signal (indicative of an electrical field resulting from an electrical signal propagated by adjacent proximal sensory nerve fibers away from the target DRG) or a DRG signal (indicative of an electrical field produced by cell bodies of primary sensory neurons within the target DRG and resulting from an electrical signal propagated by sensory nerve fibers within the target DRG) is / are obtained and analyzed. Delivery of electrical stimulation is turned on and off and / or at least one of pulse amplitude, pulse width and / or pulse repetition rate is / are adjusted based on results of the analysis.
Owner:TC1 LLC

Methods and systems for automatically turning on and off drg stimulation and adjusting drg stimulation parameters

Methods and systems described herein can be used to automatically turn on and off stimulation of a target dorsal root ganglion (DRG) and / or adjust stimulation parameters. At least one of an input signal (indicative of an electrical field resulting from an electrical signal propagated by adjacent distal sensory nerve fibers toward the target DRG), an output signal (indicative of an electrical field resulting from an electrical signal propagated by adjacent proximal sensory nerve fibers away from the target DRG) or a DRG signal (indicative of an electrical field produced by cell bodies of primary sensory neurons within the target DRG and resulting from an electrical signal propagated by sensory nerve fibers within the target DRG) is / are obtained and analyzed. Delivery of electrical stimulation is turned on and off and / or at least one of pulse amplitude, pulse width and / or pulse repetition rate is / are adjusted based on results of the analysis.
Owner:ST JUDE MEDICAL LUXEMBOURG HLDG SMI S A R L SJM LUX SMI

Detection of neuropeptides associated with pelvic pain disorders and uses thereof

InactiveUS20120058950A1Effective to treat the pelvic pain disorderRelieve symptomsBiocideOrganic active ingredientsDense Core VesiclesSensory neuron
Diagnostic assessment and therapeutic treatment of pelvic pain disorders, including bladder disorders, bowel disorders, and / or reproductive tissue or organ disorders that are characterized by increased expression of the neuropeptides CGRP and / or PACAP. Additionally, applicants have developed a transgenic non-human model for pelvic pain disorders, where the transgenic animal expresses in bladder sensory neurons a recombinant neuropeptide implicated in the pelvic pain disorder.
Owner:UNIVERSITY OF VERMONT +1

Methods of generating human inner ear sensory epithelia and sensory neurons

Provided herein are methods for directing differentiation of human pluripotent stem cells into inner ear sensory epithelia and sensory neurons. More particularly, provided herein are methods for obtaining three-dimensional cultures comprising human pluripotent stem cell-derived pre-otic epithelium, otic vesicles, and inner ear sensory epithelia containing hair cells, sensory neurons, and supporting cells.
Owner:INDIANA UNIV RES & TECH CORP

Pain signaling molecules

InactiveUS20050164288A1Inhibit expressionExpression of the polypeptides of the invention is preventedAnimal cellsPeptide/protein ingredientsG protein-coupled receptorSensory neuron
The invention relates generally to novel genes expressed in normal but not Neurogenin-1-deficient animals. The invention relates specifically to a novel family of G protein-coupled receptors and a novel family of two-transmembrane segment proteins that are expressed in dorsal root ganglia, and a method of screening for genes specifically expressed in nociceptive sensory neurons.
Owner:CALIFORNIA INST OF TECH

Serum-free induction method of sensory neuronal cells

According to the novel human sensory neuron induction culture system provided by the invention, the combination of the small-molecule inhibitor LY2157299 and the growth factor is added into the serum-free basal culture medium, so that compared with a serum-containing induction method, the efficiency of converting pluripotent stem cells into sensory neurons is greatly improved, and the induction efficiency of the pluripotent stem cells is improved. In addition, the expression of various ion channel proteins is obviously improved, so that various induced pluripotent stem cells with different sources are successfully induced into sensory neurons.
Owner:IREGENE THERAPEUTICS LTD

Sensory stimulation apparatus

Apparatus for providing sensory stimulation to a subject, the apparatus including an input that acquires input signals indicative of a stimulatory input, a signal generator, a coil system including atleast one coil and an electronic controller operating in accordance with software instructions. In use, the controller receives the input signals from the input, performs analysis of the input signals and, uses results of the analysis to cause the signal generator to generate stimulation signals, the stimulation signals being applied to the coil system to thereby generate a stimulatory electromagnetic field in a target region of the subject, the stimulatory electromagnetic field being configured to selectively activate sensory neurons to thereby stimulate the subject in accordance with the stimulatory input.
Owner:AUGMENTED BIONICS PTY LTD

Antibody binding to lysophosphatidylglucoside, and composition comprising the same

InactiveUS20130142813A1Suppressing repellent effect of Lyso-PtdGlcPromote repairNervous disorderImmunoglobulins against animals/humansNeuronal damageAxon extension
In order to identify a factor demonstrating a repellent effect on axon extension of a neuron, lysophosphatidylglucoside (LPG) has been found to have an activity as a chemorepellent effect on axon guidance of a DRG sensory neuron specific to a neuron expressing TrkA, an NGF receptor.In addition, it has been found out that suppressing the function of LPG makes it possible to suppress a repellent effect of LPG on axon extension of a neuron expressing TrkA. A molecule capable of suppressing the function of LPG can be a composition promoting repairing of a neural circuit in neuronal damages and the like.
Owner:RIKEN

Antagonists of the transient receptor potential vanilloid 1 and uses thereof

One of the major disabling symptoms of gastroparesis is nausea and vomiting which can be difficult to control with currently available treatments. It is postulated that signaling of gastrointestinal causes of nausea starts with activation of vagal afferent nerves that trigger the central emetic pathway. Most vagal afferent nerves are unmyelinated C-fibers, many of which express the vanilloid receptor TRPV1 and respond to capsaicin. Resiniferatoxin is a very potent capsaicin analogue that has a much more favorable ratio of desensitization to excitation than capsaicin leading to more effective desensitization without irritation. The present invention demonstrates that desensitization of TRPV1 responsive gastric sensory neurons would attenuate nausea and vomiting.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Methods of generating human inner ear sensory epithelia and sensory neurons

Provided herein are methods for directing differentiation of human pluripotent stem cells into inner ear sensory epithelia and sensory neurons. More particularly, provided herein are methods for obtaining three-dimensional cultures comprising human pluripotent stem cell-derived pre-otic epithelium, otic vesicles, and inner ear sensory epithelia containing hair cells, sensory neurons, and supporting cells.
Owner:INDIANA UNIV RES & TECH CORP

Neuronal signal system for behavior modification

The present invention relates to a system for stimulating the sensory cortex of an individual, comprising: means for obtaining a neuronal stimulation signal adapted to provide a movement cue for the individual and means for transmitting the neuronal stimulation signal to an electric contact of a neuronal stimulation electrode that is already implanted into the brain of the individual for a purpose different from providing the movement cue.The present invention further relates to a system for communicating proprioceptive information to an individual, comprising means for obtaining information about the body posture of the individual; means for determining, based on the obtained information, a neuronal stimulation signal to be applied to at least one afferent axon targeting at least one sensory neuron in the cortex of the individual, wherein the determined neuronal stimulation signal corresponds to the proprioceptive information to be communicated and means for transmitting the determined neuronal stimulation signal to a neuronal stimulation means of the individual adapted to apply the determined neuronal stimulation signal to the at least one afferent axon.The present invention further relates to a system for communicating movement information to an individual, comprising means for providing a first neuronal stimulation signal to be applied to the cortex of an individual adapted to provide a movement cue for the individual and means for providing a second neuronal stimulation signal to be applied to the cortex of the individual adapted to provide proprioceptive information to the individual, wherein the first and the second neuronal stimulation signal are adapted to be applied together to the cortex of the individual.
Owner:CEREGATE GMBH

Treatment of amyotrophic lateral sclerosis with lactate

Amyotrophic lateral sclerosis (ALS) is a devastating disease that leads initially to death of motor nerves with some progression to death of sensory and autonomic nerves. Experimental work shows that more electrical energy is required to successfully stimulate motor vs. sensory nerve components of a nerve and longer vs. shorter components of a nerve. This discovery explains sparing of the nerves of ocular motion and nerves of rectal and urethral sphincters in patients suffering from ALS and supports the energy hypothesis of ALS. Neurons and peripheral nerves are dependent upon glial cells and oligodendrocytes respectively to support their high energy demands. These supporting cells shuttle lactate to neurons and nerves. Lactate is required to sustain contraction of skeletal muscle. Administration of racemic or L-lactate in an amount greater than the capacity of the liver to oxidize will increase the available lactate to nerves and neurons and improve the symptoms of ALS.
Owner:GOLDBERG JOEL STEVEN

Method for observing DRG and spinal cord structure of animal, and recording spinal cord electrical activities of animal

The invention relates to a method for observing the DRG and spinal cord structure of an animal, and recording spinal cord electrical activities of the animal. The method comprises the following steps: (1) a DRG operation; (2) a DRG virus injection; (3) an operation for simultaneous observing the spinal cord side axon and the DRG; (4) an operation for observing the dorsal axon; (5) a spinal operation for inserting potential difference monitoring electrodes; (6) imaging. The method is used for observing the comparison between the dorsal axon and the ventral axon of the animal as well as the spinal cord electrical activities, so that repeated operations during the imaging can be avoided, the pain and pressure suffered by a tested animal can be relieved, the spinal cord side of the animal can be observed, a comparative research on the motor neuron axon and the sensory neuron axon of the animal can be achieved, and the spinal cord dorsal side of the animal can be observed when the animal is sober; through the adoption of the method, all-directional connection of the whole nerve system can be achieved, researches on the structure and function operating mechanism of the whole nerve system can be promoted, and a feasible method for integrated researches and analysis of sleeping, learning and other animal behaviors can be provided.
Owner:张金辉 +4

Methods of identifying, isolating and using odorant and aroma receptors

Provided here are new methods to identify specific families of mammalian odorant receptors for odorants or aroma, particularly indole and skatole malodors and their use in assays that may be used to discover compounds that modulate (blocking, enhancing, masking or mimicking compounds) their activity. Orphan mouse odorant receptors are identified from olfactory sensory neurons that respond to target compounds. The resulting receptors as well as their human counterparts can be screened in assays against test compounds to confirm their identity as odorant or aroma receptors, particularly malodor receptors and subsequently discover for example modulators that inhibit the perception of the malodor in humans.
Owner:FIRMENICH SA

MSCs (Mesenchymal stem cells) sourced schwann cell trophoblast type axon growth method of sensory neurone

The invention discloses an MSCs (Mesenchymal stem cells) sourced schwann cell trophoblast type axon growth method of sensory neurone. The method comprises the following steps: S1, culturing P2-generation umbilical cord MSCs with umbilical cord wharton jelly of a newborn through an MSCs culture medium; S2, suspending the P2-generation umbilical cord MSCs through the MSCs culture medium; inoculatingto a recombinant human laminin and recombinant human vitronectin coated cell culture plate for culturing until the confluence reaches 60-70%; and preparing neuroepithelium pre-induced cell through aneural differentiation culture medium; S3, culturing P0-generation SCs with the neuroepithelium pre-induced cell through an SCs culture medium; and performing a subculture until P1 generation is obtained; S4, preparing an SCs trophoblast through P1-geneation SCs; and S5, preparing DRG (Dorsal root ganglion) sensory neurone cells; and performing co-culture through the SCs trophoblast and the DRG sensory neurone cells. According to the method, a new ideal is provided for cell therapy on nerve injury and repair of central nervous system.
Owner:北京再生生物科技研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products